Completed PHASE1 INTERVENTIONAL 1-arm NCT01044524

Study to Investigate ADME of 14C Labeled SLV334 After an i.v. Infusion

An Open Label Study to Determine ADME of 14C Labeled SLV334 and Its Metabolites After Single Intravenous Dose Infusion

Sponsor: Solvay Pharmaceuticals

Interventions SLV 334

Updated 6 times since 2017 Last updated: Sep 16, 2010 Started: Feb 28, 2010 Primary completion: Mar 31, 2010 Completion: Mar 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01044524, this PHASE1 trial focuses on Pharmacology, Clinical and remains completed. Sponsored by Solvay Pharmaceuticals, it has been updated 6 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Feb 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Solvay Pharmaceuticals

Data source: Solvay Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zuidlaren, Netherlands